Agilon Health Investors Face March 2 Deadline in Securities Class Action Over 2025 Guidance

Several firms are vying to lead the case after the August 2025 disclosure triggered a sharp share selloff.

Overview

Complaints cover investors who bought agilon health securities between February 26, 2025 and August 4, 2025.
Plaintiffs allege the company issued 2025 guidance that was not achievable and overstated the immediate benefits of risk‑reduction “strategic actions.”
On August 4, 2025, agilon suspended full‑year guidance, reported quarterly results, and disclosed CEO Steven Sell’s departure described in an 8‑K as a termination without cause.
Shares fell roughly 51–52% on August 5, 2025, with one filing noting a close at $0.8801 following the disclosures.
Bernstein Liebhard, Portnoy, Faruqi & Faruqi, The Gross Law Firm, and Levi & Korsinsky are soliciting investors and information, with March 2, 2026 set as the deadline to seek lead‑plaintiff status.